Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Rilvegostomig (AZD2936) for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of lung cancer known as Non-small Cell Lung Cancer (NSCLC), specifically in its advanced stages. The study involves a treatment called Rilvegostomig, also known by its code name AZD2936. This treatment is a special kind of protein designed to target and block certain pathways in the body that cancer cells use to grow. The purpose of the study is to evaluate the safety and effectiveness of this treatment in patients with advanced or metastatic NSCLC.

Participants in the study will receive the treatment as a solution through an infusion, which means it will be administered directly into the bloodstream. The study will be conducted in different parts, each focusing on different aspects of the treatment, such as its safety and how well it works against the cancer. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatment. The study will also monitor how the body processes the treatment and any potential side effects that may occur.

The trial will take place over several years, allowing researchers to gather comprehensive data on the treatment's impact on the disease. Throughout the study, participants will undergo regular check-ups and tests to assess their health and the progress of the treatment. The ultimate goal is to determine if Rilvegostomig can be a safe and effective option for treating advanced stages of Non-small Cell Lung Cancer.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient provides written informed consent. This confirms understanding of the study and agreement to participate.

    Eligibility is confirmed based on criteria such as age (18 or above), adequate organ function, and specific medical conditions related to non-small cell lung cancer (NSCLC).

  2. Step 2

    Initial assessment

    An initial assessment is conducted to evaluate the patient's health status. This includes checking vital signs and laboratory parameters.

    The patient's performance status is assessed using the ECOG scale, which measures daily living abilities.

  3. Step 3

    Treatment administration

    The patient receives the medication AZD2936, which contains the active substance rilvegostomig. This is administered as a solution for infusion through intravenous use.

    The dosage and frequency of administration are determined based on the specific part of the study the patient is enrolled in.

  4. Step 4

    Monitoring and follow-up

    Throughout the study, the patient is monitored for safety and tolerability of the medication. This includes tracking any adverse events or immune-mediated reactions.

    Regular assessments are conducted to evaluate the medication's effect on the cancer, including measuring tumor response and progression.

  5. Step 5

    Study completion

    The study is estimated to conclude by January 1, 2026. Upon completion, a final assessment is conducted to evaluate the overall outcomes and any long-term effects of the treatment.

Who can join the trial?

10 criteria

  • You must provide written informed consent, which means you agree to participate after understanding the study details.
  • Your bone marrow, liver, and kidney must be working well enough to participate.
  • You need to be 18 years or older.
  • If you are in Part A or Part B, you must have unresectable stage III or stage IV non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. If you are in Part C or Part D, you must have stage IV NSCLC that cannot be cured with surgery or radiation.
  • You need to have a documented PD-L1 expression, which is a specific protein found in your cancer cells, confirmed by a local test.
  • If you are in Part A or Part B, your cancer must have progressed during treatment with a regimen that includes a checkpoint inhibitor (CPI), a type of cancer treatment.
  • If you are in Part C or Part D, you must not have had any previous immuno-oncology (IO) treatment for metastatic NSCLC.
  • You need to have an ECOG performance status of 0 or 1, which means you are fully active or have some symptoms but can still carry out light work.
  • You should have a life expectancy of at least 12 weeks when you join the study.
  • You must have at least one measurable lesion according to specific criteria used to assess cancer size and response to treatment.

Who cannot join the trial?

8 criteria

  • Patients who have a different type of cancer than the one being studied.
  • Patients who have had a recent major surgery or are recovering from one.
  • Patients who have an active infection that requires treatment.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a history of severe allergic reactions to similar medications.
  • Patients who are currently participating in another clinical trial.
  • Patients who have a medical condition that the study doctors believe would make it unsafe for them to participate.
  • Patients who are unable to follow the study procedures or instructions.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

AZD2936 is a bispecific antibody designed to target two proteins, TIGIT and PD-1, which are involved in the immune system's response to cancer. By blocking these proteins, AZD2936 aims to enhance the body's ability to fight cancer cells, particularly in patients with advanced or metastatic non-small cell lung cancer. This medication is being studied to determine its safety, how it is processed in the body, its effects on the immune system, and its effectiveness in treating cancer.

What is already known about the treatment

Rilvegostomig – This medication is administered as an injection and is currently being studied in clinical trials for its potential use in treating advanced or metastatic non-small cell lung cancer (NSCLC). It is in the investigational stage, with ongoing research to evaluate its safety and effectiveness. The main therapeutic indication is for patients with stage III unresectable or stage IV NSCLC. Rilvegostomig works by targeting specific proteins involved in cancer cell growth, specifically acting as a bispecific antibody against TIGIT and PD-1, which are proteins that help cancer cells evade the immune system. It is classified pharmacologically as an immunotherapy agent.

Investigated diseases

  • Advanced Non-Small Cell Lung Cancer

    This is a type of lung cancer that has spread beyond the lungs to other parts of the body. It is characterized by the uncontrolled growth of abnormal cells in the lung tissues. As the disease progresses, it can invade nearby tissues and organs, making it more challenging to treat. Symptoms may include persistent cough, chest pain, and difficulty breathing. The disease is often diagnosed at an advanced stage due to its subtle early symptoms.

  • Metastatic Non-Small Cell Lung Cancer

    This form of lung cancer occurs when cancer cells from the lung spread to other parts of the body, such as the brain, bones, or liver. It is a progression of non-small cell lung cancer where the cancerous cells travel through the bloodstream or lymphatic system. Symptoms can vary depending on the organs affected by the metastasis. Common signs include weight loss, fatigue, and pain in the affected areas. The spread of cancer cells makes it more complex to manage and treat.

  • Stage III Unresectable Non-Small Cell Lung Cancer

    This stage of lung cancer indicates that the cancer has spread to nearby tissues or lymph nodes but cannot be surgically removed. The tumor may be too large or located in a position that makes surgery risky. Symptoms often include persistent cough, shortness of breath, and chest pain. The disease may also cause swelling in the face or neck due to pressure on blood vessels. Treatment focuses on controlling the growth and spread of the cancer.

  • Stage IV Non-Small Cell Lung Cancer

    This is the most advanced stage of non-small cell lung cancer, where the cancer has spread to distant parts of the body. It is characterized by the presence of tumors in organs beyond the lungs, such as the brain or liver. Symptoms can be widespread and include severe fatigue, weight loss, and pain in various parts of the body. The disease is often diagnosed through imaging tests that reveal the extent of the spread. Management focuses on alleviating symptoms and improving quality of life.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2023-508262-15-00Protocol codeD7020C00001Estimated enrolment213 patientsSponsorAstraZeneca AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.